Skip to main content

Table 1 Clinical characteristics of the subjects at baseline

From: Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case–control study

  Teneligliptin Sitagliptin P value
Age (years) 70.0 ± 3.9 65.4 ± 10.7 0.912
Sex (M/F) 22 (10/12) 23 (12/11) 0.652
Body mass index (kg/m2) 22.1 ± 3.4 23.6 ± 1.9 0.209
HbA1c  % (NGSP) 8.1 ± 1.4 8.0 ± 1.7 0.739
Duration of diabetes (years) 13.2 ± 3.0 12.8 ± 6.3 0.952
eGFR (mL/min/1.73m2) 43.5 ± 15.8 39.6 ± 15.9 0.394
Urinary albumin excretion (µg/g Cre) 418.4 (93.5–299.5) 485.0 (67.0–729.3) 0.750
Statins n (%) 16 (72.7 %) 17 (80.9 %) 0.627
ACEI or ARB n (%) 20 (90.1 %) 20 (95.2 %) 0.578
Biguanide n (%) 3 (13.6 %) 4 (19.0 %) 0.631
Sulfonylurea or glinide n (%) 7 (31.8 %) 9 (42.9 %) 0.454
Insulin n (%) 12 (54.5 %) 9 (42.9 %) 0.443
  1. Data are mean ± SD or median and interquartile range
  2. ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker